Double-blind study of clozapine dose response in chronic schizophrenia

American Journal of Psychiatry

Volumn 156, Issue 11, 1999, Pages 1744-1750

  Simpson, George M ^a   Josiassen, Richard C ^b   Stanilla, Joseph K ^b   De Leon, Jose ^b   Nair, Chand ^b   Abraham, George ^b   Odom White, Aruby ^b   Turner, Ralph M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; MALE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032730108     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Delay J, Deniker P: Le traitement des psychoses par une methode neurolytique derivée d'hibemotherapie; le 4560 RP utilisée seul en cure prolongée et continuée. Congrès Des Médecins Alienistes et Neurologistes de France et des Pays du Langue Française 1952; 50:503-513
2. Baldessarinl RJ, Cohen BM, Teicher ME: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45:79-91
3. Simpson GM, Varga E: Clozapine - a new antipsychotic agent. Curr Ther Res 1974; 18:679-686
4. Simpson GM, Cooper TB: Clozapine plasma levels and convulsions. Am J Psychiatry 1978; 135:99-100
5. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
6. Pollack S, Lieberman JA, Fleischhacker WW, Borenstein M, Safferman AZ, Hummer M, Kurz M: A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. Psychopharmacol Bull 1995; 31:315-320
7. Melizer HY: Duration of a clozapine trial in neuroleptic-resistant schizophrenia (letter). Arch Gen Psychiatry 1989; 46:672
8. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337:809-815
9. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
10. Woerner MG, Mennuzza S, Kane JM: Anchoring the BPRS-A: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112-117
11. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1981
12. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86:420-428
13. Kirk RE: Experimental Design: Procedures for the Behavioral Sciences, 3rd ed. Pacific Grove, Calif, Brooks/Cole, 1995
14. Nair CJ, de Leon J, Simpson GM, Josiassen RC: Therapeutic effects of clozapine on tardive dyskinesia. Cognitive and Behavioral Practice 1998; 5:119-127
15. Nair CJ, Josiassen RC, Abraham G, Stanilla JK, Tracy JI, Simpson GM: Does akathisia influence psychopathology in psychotic patients treated with clozapine? Biol Psychiatry 1999; 45:1376-1383
16. Lindenmayer JP, Grochowski S, Mabugat L: Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1993; 14:201-204
17. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
18. Abraham G, Nair C, Tracy JI, Simpson GM, Josiassen RC: The effects of clozapine on symptom clusters in treatment-refractory patients. J Clin Psychopharmacol 1997; 17:49-53
19. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153:1579-1584
20. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13:383-390
21. Perry PJ, Miller DD, Arndt SV, Cadoret RJ: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148:231-235; correction, 148:1427
22. Potkin SG, Bera R, Gulaskaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telfold J, Plon L, Plon H, Park L, Chang J-J, Oldroyd J, Cooper T: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55(Sept suppl B):133-136
23. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152:170-182